Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2031567
Max Phase: Preclinical
Molecular Formula: C21H20FNO5S2
Molecular Weight: 449.53
Molecule Type: Small molecule
Associated Items:
ID: ALA2031567
Max Phase: Preclinical
Molecular Formula: C21H20FNO5S2
Molecular Weight: 449.53
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(F)ccc1S(=O)(=O)N(C(=O)C1CCCCC1)c1ccc2oc(=O)sc2c1
Standard InChI: InChI=1S/C21H20FNO5S2/c1-13-11-15(22)7-10-19(13)30(26,27)23(20(24)14-5-3-2-4-6-14)16-8-9-17-18(12-16)29-21(25)28-17/h7-12,14H,2-6H2,1H3
Standard InChI Key: YZVAEDHJAMFTNC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 449.53 | Molecular Weight (Monoisotopic): 449.0767 | AlogP: 4.60 | #Rotatable Bonds: 4 |
Polar Surface Area: 84.66 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 5.42 | CX LogD: 5.42 |
Aromatic Rings: 3 | Heavy Atoms: 30 | QED Weighted: 0.58 | Np Likeness Score: -1.65 |
1. Nagarajan S, Skoufias DA, Kozielski F, Pae AN.. (2012) Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors., 55 (6): [PMID:22309208] [10.1021/jm201290v] |
Source(1):